This patent grant is a routine IP milestone with no immediate revenue or clinical impact. Monitor for future clinical trial updates on CMND-100 or other pipeline candidates, as well as any financing events given the $3M market cap.
Price Chart
Executive Summary
Clearmind Medicine announced a new U.S. patent (No. 12,350,242) for its MEAI molecule covering binge behavior regulation, expanding its global patent portfolio to 32 granted patents. This is a routine IP milestone for a clinical-stage biotech with no financial data or clinical results provided.
Key Facts
- U.S. Patent No. 12,350,242 titled 'BINGE BEHAVIOR REGULATORS' granted by USPTO
- Patent covers Clearmind's MEAI molecule for regulating binge behaviors including excessive drinking, eating, and gambling
- Global patent portfolio now includes 32 granted patents across 19 patent families
- Company is clinical-stage, pre-revenue biotech focused on non-hallucinogenic neuroplastogen-derived therapeutics
Financial Impact
No financial figures or revenue disclosed; pre-revenue clinical-stage company
Risk Factors
- Clinical-stage biotech with no approved products or revenue
- Forward-looking statements about patent issuance and commercialization are inherently uncertain
- Micro-cap ($3M) stock is highly volatile and subject to liquidity risks
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3314092 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | 6-K | $6.00 | awaiting T+60 | — | $5.87 (+2.17%) |
Oct 13, 2026 13d ago | 6-K | $6.23 | awaiting T+60 | — | $5.87 (−5.78%) |
Oct 8, 2026 18d ago | 6-K | $6.60 | awaiting T+60 | — | $5.87 (−11.06%) |
Oct 7, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $5.87 (−11.06%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $5.87 (+590.59%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $5.87 (+590.59%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $5.87 (−14.48%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $5.87 (+521.82%) |
Sep 8, 2026 6w ago | 6-K | $1.03 | awaiting T+60 | — | $5.87 (+469.90%) |
Sep 4, 2026 7w ago | 6-K | $1.16 | awaiting T+60 | — | $5.87 (−406.03%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers